

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761175Orig1s000

OTHER ACTION LETTERS



BLA 761175

COMPLETE RESPONSE

Biocon Biologics Inc.
Attention: Paul V. Thomas
Global Head, Portfolio and Program Management
245 Main St, 2nd Floor
Cambridge, MA 02142

Dear Paul V. Thomas:

Please refer to your biologics license application (BLA) submitted and received on December 27, 2019, under section 351(k) of the Public Health Service Act for MYL-1402O.

MYL-1402O is a proposed biosimilar to US-licensed Avastin (bevacizumab) (BLA 125085).

We acknowledge receipt of your amendment dated August 11, 2023, which constituted a complete response to our February 6, 2023, action letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

FACILITY INSPECTIONS

Following a CGMP inspection of Biocon Biologics Limited, Bengaluru, Karnataka, India (FEI 3003981475) listed in this application, FDA conveyed deficiencies to the representative of the facility. The facility should provide a satisfactory response to these deficiencies to the FDA office indicated on the FDA 483 prior to submission of your complete response. The facility's satisfactory responses are dependent on FDA's determination that the facility has come into compliance with CGMP and may require re-inspection of the facility. The deficiencies identified during the inspection may not be specific to your pending application, therefore, you should coordinate with the facility for timely resolution. Your complete response should include the date(s) of the facility's response(s) to the FDA Form 483. Refer to Compliance Program CP 7356.002 for guidance on post inspection activities.

PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources¹ and Pregnancy and Lactation Labeling Final Rule² websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) – a checklist of important format items from labeling regulations and guidances. In addition, we encourage you to review the FDA guidance for industry *Labeling for Biosimilar Products*.

CARTON AND CONTAINER LABELING

We reserve comment on the proposed labeling until the application is otherwise adequate.

PROPRIETARY NAME

Please refer to correspondence dated, November 3, 2023, which addresses the proposed proprietary name, Jobevne. This name was found conditionally acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to all of the application deficiencies that have been identified in this letter.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update. The safety update should include data from all nonclinical and clinical studies of the product under consideration regardless of indication, dosage form, or dose level.

- (1) Describe in detail any significant changes or findings in the safety profile and their relevance, if any, to whether there may be clinically meaningful differences between the proposed biosimilar product and the U.S.-licensed reference product.
- (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
 - Present new safety data from the clinical studies for the proposed indication using the same format as the original BLA submission.

¹ <https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources>

² <https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule>

- Present tabulations of the new safety data combined with the original BLA data.
 - Include tables that compare frequencies of adverse events in the original BLA with the retabulated frequencies described in the bullet above.
- (3) Present a retabulation of the reasons for premature study discontinuation by incorporating the drop-outs from the newly completed studies. Describe any new trends or patterns identified.
- (4) Provide case report forms and narrative summaries for each subject who died during a clinical study or who did not complete a study because of an adverse event. In addition, provide narrative summaries for serious adverse events.
- (5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original BLA data.
- (6) Provide updated exposure information for the clinical studies (e.g., number of subjects, person time).
- (7) Provide a summary of worldwide experience on the safety of this product, including adverse events known to be associated with the use of the product and immunogenicity. Include an updated estimate of use for this product marketed in other countries.
- (8) Provide English translations of current approved foreign labeling not previously submitted.

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b)). If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 601.3(c). You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "**RESUBMISSION**" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting,

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

submit your meeting request as described in the draft guidance for industry *Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products*.

The product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call Nataliya Fesenko, Pharm.D., Senior Regulatory Health Project Manager, at (240) 402-6376.

Sincerely,

{See appended electronic signature page}

Lola Fashoyin-Aje, M.D., M.P.H.
Deputy Director
Division of Oncology 3
Office of Oncologic Diseases
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

IBIOLA A FASHOYIN-AJE
02/07/2024 07:57:34 PM



BLA 761175

COMPLETE RESPONSE

Mylan Pharmaceuticals Inc.
Attention: S. Wayne Talton
Head of Global Regulatory Affairs
3711 Collins Ferry Road
Morgantown, WV 26505

Dear Mr. Talton:

Please refer to your biologics license application (BLA) submitted and received December 27, 2019, under section 351(k) of the Public Health Service Act for MYL-1402O.

MYL-1402O is a proposed biosimilar to US-licensed Avastin (bevacizumab) (BLA 125085).

We have completed our review of this application, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

FACILITY INSPECTIONS

During a recent inspection of the BIOCON BIOLOGICS INDIA LIMITED (FEI: 3003981475) manufacturing facility for this application, our field investigators conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources¹ and Pregnancy and Lactation Labeling Final Rule² websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) – a checklist of important format items

¹ <https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources>

² <https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule>

from labeling regulations and guidances. In addition, we encourage you to review the FDA guidance for industry *Labeling for Biosimilar Products*.

CARTON AND CONTAINER LABELING

We reserve comment on the proposed labeling until the application is otherwise adequate.

PROPRIETARY NAME

Please refer to correspondence dated, April 13, 2022 which addresses the proposed proprietary name, Jobevne. This name was found acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to the application deficiencies.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update. The safety update should include data from all nonclinical and clinical studies of the product under consideration regardless of indication, dosage form, or dose level.

- (1) Describe in detail any significant changes or findings in the safety profile and their relevance, if any, to whether there may be clinically meaningful differences between the proposed biosimilar product and the U.S.-licensed reference product.
- (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
 - Present new safety data from the clinical studies for the proposed indication using the same format as the original BLA submission.
 - Present tabulations of the new safety data combined with the original BLA data.
 - Include tables that compare frequencies of adverse events in the original BLA with the retabulated frequencies described in the bullet above.
- (3) Present a retabulation of the reasons for premature study discontinuation by incorporating the drop-outs from the newly completed studies. Describe any new trends or patterns identified.
- (4) Provide case report forms and narrative summaries for each subject who died during a clinical study or who did not complete a study because of an adverse event. In addition, provide narrative summaries for serious adverse events.

- (5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original BLA data.
- (6) Provide updated exposure information for the clinical studies (e.g., number of subjects, person time).
- (7) Provide a summary of worldwide experience on the safety of this product, including adverse events known to be associated with the use of the product and immunogenicity. Include an updated estimate of use for this product marketed in other countries.
- (8) Provide English translations of current approved foreign labeling not previously submitted.

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b)). If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 601.3(c). You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "**RESUBMISSION**" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry *Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants*.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call Nataliya Fesenko, Pharm.D., Senior Regulatory Health Project Manager, at (240) 402-6376.

Sincerely,

{See appended electronic signature page}

Lola Fashoyin-Aje, M.D., M.P.H
Deputy Director
Division of Oncology 3
Office of Oncologic Diseases
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

IBIOLA A FASHOYIN-AJE
02/06/2023 04:16:15 PM

7